Comparing Otezla, study drug SFA-002, and placebo for plaque psoriasis
Part of Skin clinical trials.
This study compares two oral medications (Otezla and an experimental drug called SFA-002) against a placebo (a pill with no active ingredients) for people with mild to moderate plaque psoriasis. The goal is to see which treatment works better and if SFA-002 can safely help clear your skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have mild to moderate plaque psoriasis for at least 6 months.
- Your psoriasis should cover about 10% to 15% of your skin (roughly the area of 10 to 15 palm-sized patches).
- You cannot have other skin conditions that would make it hard to tell if the treatment is working.
- You cannot have taken apremilast (Otezla) or SFA-002 before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
This trial tests an investigational drug called ORKA-002 for people with moderate-to-severe plaque psoriasis. It aims to see how well different doses work and if they are safe. You may qualify if your psoriasis covers at least 10% of your body or if it has not responded well enough to other treatments.
This study tests a new injectable medicine for people with moderate-to-severe plaque psoriasis. It aims to see if it is safe and effective at reducing symptoms like redness and scaling.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study tests whether a new ointment called RSS0393 can safely and effectively treat plaque psoriasis (a common skin condition causing red, scaly patches). You would apply it to affected skin areas and be compared to people using a placebo (inactive cream) to see if the treatment works.
Hear when a new Psoriasis (PsO) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.